Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share and Trends 2024 to 2034

Cancer Immunotherapy Drug Discovery Outsourcing Market Size and Forecast 2024 to 2034

The global cancer immunotherapy drug discovery outsourcing market size is predicted to be worth around USD 3.87 billion by 2034 from USD 1.52 billion in 2024, at a CAGR of 9.83% between 2024 and 2034. The North America cancer immunotherapy drug discovery outsourcing market size reached USD 520 million in 2023. Cancer immunotherapy drug discovery outsourcing helps to make it easier for it to find and remove cancer cells or help the immune system work harder. Many immunotherapy drugs help to fight cancer which helps to the growth of the market.

Cancer Immunotherapy Drug Discovery Outsourcing Market Key Takeaways

• North America dominated the cancer immunotherapy drug discovery outsourcing market with the largest market share of 38% in 2023.
• Asia Pacific is estimated to be the fastest-growing during the forecast period of 2024-2033.
• By service, the target identification and validation segment dominated while the market in 2023.
• By service, the lead screening and characterization segment is anticipated to be the fastest-growing during the forecast period.
• By cancer type, the lung cancer segment accounted for the largest market share of 26% in 2023.
• By cancer, the prostate cancer segment is estimated to be the fastest-growing during the forecast period.
• By drug, the monoclonal antibodies segment has recorded more than 64% of market share in 2023.
• By drug, the cancer vaccines and oncolytic viral therapy segment is expected to be the fastest-growing during the forecast period.

U.S. Cancer Immunotherapy Drug Discovery Outsourcing Market Size and Growth 2024 to 2034

The U.S. cancer immunotherapy drug discovery outsourcing market size was exhibited at USD 370 million in 2023 and is projected to be worth around USD 1,050 million by 2034, poised to grow at a CAGR of 9.94% from 2024 to 2034.

North America dominated the cancer immunotherapy drug discovery outsourcing market in 2023. The presence of many biotech and pharmaceutical companies leads to the growth of the market in the North American region. Key CROs and government initiatives can help grow the market for cancer immunotherapy drug discovery outsourcing. The United States is leading the growth of the market in the North American region.

• In June 2024, a mid-stage study to evaluate a new drug combination as a first-line treatment for patients living with metastatic pancreatic cancer was launched by the University of Glasgow and NHS Greater Glasgow and Clyde.

Asia Pacific is estimated to be the fastest-growing during the forecast period of 2024-2033. Many market players comply with regulatory guidelines and good laboratory practices (GLP), use advanced technologies, and the rising CROs that help the growth of the cancer immunotherapy drug discovery outsourcing market in the Asia Pacific region.

• In March 2024, in India, the cancer drug ‘Olaparib,’ a PARP inhibitor under the brand name IBYRA, was launched by Zydus Lifesciences. The drug helps target genetic mutations in specific types of cancers and more effective treatment.
• In April 2024, President Droupadi Murmu launched India’s first indigenously developed CAR-T cell therapy for cancer treatment at the Indian Institute of Technology (IIT) Bombay.

Market Overview

The cancer immunotherapy drug discovery outsourcing market involves collaboration with service providers or outside companies to complete different stages of drug development, like clinical trial support, preclinical testing, lead optimization, and target identification, with a focus on generating cancer immunotherapy drugs. The cancer immunotherapy drug is a type of treatment that aims to control and boost the body’s immune system to fight cancer. It involves many strategies, including oncolytic viruses, adoptive T-cell therapies, cancer vaccines, immune checkpoint inhibitors, and monoclonal antibodies. These factors help to the growth of the market.

Cancer Immunotherapy Drug Discovery Outsourcing Market Growth Factors

• The benefits of cancer immunology drug discovery outsourcing include innovative technology, resources, and knowledge which contribute to the growth of the market.
• The cancer immunotherapy drug is the type of treatment that aims to control and boost the body’s immune system to fight cancer which helps to the growth of the market.
• It involves many strategies, including oncolytic viruses, adoptive T-cell therapies, cancer vaccines, immune checkpoint inhibitors, and monoclonal antibodies, which help the growth of the cancer immunotherapy drug discovery outsourcing market.
• These help to improve immune response and to prevent the suppression of the immune system that may enable tumors to grow, which helps the growth of the market.

What are the benefits of AI in the Cancer Immunotherapy Drug Discovery Outsourcing?

Artificial intelligence (AI) and machine learning (ML) algorithms analyze large data sets, identify biomarkers, and predict potential drug candidates. These technologies can help improve target identification accuracy and speed up drug discovery, which allows for the growth of the market. The use of AI in cancer immunotherapy research has the capacity to further advancements in this field and enhance patient outcomes. AI can help to discover novel immunotherapy drugs, identify potential biomarkers, and improve treatment protocols for patient response. These AI-beneficial factors help the growth of the cancer immunotherapy drug discovery outsourcing market.

• In May 2024, a new era of AI-enhanced oncology solutions called Revolution RT was launched by GE Healthcare. Revolution RT is a novel radiation therapy CT (computed tomography) solution with inventive software and hardware solutions to simplify simulation workflow and improve imaging accuracy.

Market Scope

Market Dynamics

Driver

Increasing demand for cancer immunotherapies

The increasing demand for cancer immunotherapies contributes to the growth of the market. There are several reasons doctors think that cancer immunotherapy is a good choice. When other treatments don’t work, then cancer immunotherapy can work. Some cancers, like skin cancers, can’t respond to chemotherapy or radiation, but they respond to immunotherapy. It may help other cancer treatments with better work. These factors help to the growth of the cancer immunotherapy drug discovery outsourcing market.

Restraint

Risks of cancer immunotherapy

The area where medication goes into your body may have a bad reaction, get sore, turn red, swell, itch, and hurt. There are some side effects. Some types of immunotherapies can cause problems like diarrhea, stuffy head, heart palpitations, weight gain from extra fluids, and swelling. It may harm systems and organs. Some of the cancer immunotherapy drugs may cause the immune system to attack organs like the intestines, kidneys, lungs, liver, or heart. These factors can hamper the growth of the cancer immunotherapy drug discovery outsourcing market.

Opportunity

Rising research & development initiatives

The rising research & development initiatives contribute to the growth of the cancer immunotherapy drug discovery outsourcing market. Advanced therapeutic launching options like monoclonal antibodies, HDAC inhibitors, cancer vaccines, and oncolytic cancer therapies. To overcome the challenges of cancer, immunotherapy drugs may cause the immune system to attack organs like the intestines, kidneys, lungs, liver, or heart. These factors help to the growth of the market.

Service Insights

The target identification and validation segment dominated the cancer immunotherapy drug discovery outsourcing market in 2023. Target identification and validation are key roles in cell line development for drug discovery because they ensure that the selected molecular targets, like pathways or proteins, are both related to disease therapeutic intervention, the broad foundation for the successful identification of drug therapies. Target validation helps to ensure the engagement of the target with potential therapeutic benefits like target identification in drug development. These factors help to the growth of the target identification and validation segment and contribute to the growth of the market.

The lead screening and characterization segment is anticipated to be the fastest-growing during the forecast period. The lead screening and characterization of cancer immunotherapy drug discovery play an important role in the growth of the market. It offers several benefits, including the analysis of small molecules that regulate disease conditions or protein functions. It also includes the benefits of high-throughput screening (HTS) to identify bioactive compounds, which help to discover new compounds with multiple chemical structures and mechanisms of action, lead optimization, and computer-aided drug design (CADD) to make the creation of potential medications easier These factors help the growth of the lead screening and characterization segment and contribute to the cancer immunotherapy drug discovery outsourcing market.

Cancer Insights

The lung cancer segment dominated the cancer immunotherapy drug discovery outsourcing market in 2023. Cancer immunotherapy transformed lung cancer treatment, which offers benefits including increased survival rates, durable response, new treatment options for advanced, recurrent, and early lung cancers, targeted mechanisms that help to attack cancer cells and reorganization of the immune system, combination therapies that help to enhance efficacy, overcoming drug resistance, and addressing drug heterogeneity, and CAR T-cell therapy help to treatment of lung cancer. MSKCC (Memorial Sloan Kettering Cancer Center) is a leader in evolving immunotherapy treatments.

In the last few years, the U.S. FDA (United States Food and Drug Administration) approved many immunotherapy drugs for non-small cell lung cancer. These drugs include atezolizumab (Tecentriq), durvalumab (Imfinzi), nivolumab (Opdivo), and pembrolizumab (Keytruda). These factors help to the growth of the lung cancer segment and contribute to the growth of the market.

The prostate cancer segment is estimated to be the fastest-growing during the forecast period. In the treatment of many cancers, immunotherapy plays an important role, and recent advancements in drug discovery show developments and benefits for prostate cancer, which include Sipuleucel-T, immune checkpoint inhibitors, T cell bispecific or redirectors, targeting STEAP-1 and CD-3, REGN5678 on T cells and reprogramming macrophages to promote antitumor activities. These factors help the growth of the prostate cancer segment and contribute to the growth of the cancer immunotherapy drug discovery outsourcing market.

Drug Insights

The monoclonal antibodies segment dominated the cancer immunotherapy drug discovery outsourcing market in 2023. The monoclonal antibodies play an important role in the cancer immunotherapy drug discovery outsourcing. The benefits of monoclonal antibodies include high-specificity or target-specific antigens for targeting disease cells by minimizing harm to healthy cells, potency, versatility, reduced side effects, longer half-life, and overcoming drug resistance by improving therapeutic potential. The application of monoclonal bodies in the treatment of many diseases, mainly cancers like gastric, cervical, breast, and lymphoma cancers. These factors help to the growth of the monoclonal antibodies segment and contribute to the growth of the market.

The cancer vaccines and oncolytic viral therapy segment is expected to be the fastest-growing during the forecast period. Cancer vaccines help to prevent the development of cancer. Oncolytic viruses (OVs) play an important role in cancer therapeutics or cancer immunotherapy drugs that offer many benefits, including a tolerable safety profile that does not overlap with other cancer therapeutics, promotion of antitumor immunity, induction of immunogenic cell death, delivery of many eukaryotic transgene payloads, and selective replication in tumor cells. These factors help the growth of the cancer vaccines and oncolytic viral therapy segment and contribute to the growth of the cancer immunotherapy drug discovery outsourcing market.

• In September 2023, the launch of Manaolana Oncology Inc., a new company created to advance and develop antibody-based therapies against new cancer antigens, was announced by the University of Texas MD Anderson Cancer Center and Panacea Venture.

Cancer Immunotherapy Drug Discovery Outsourcing Market Companies

• Covance, Inc.
• Molecular Imaging, Inc. (MI Bioresearch Inc.)
• STC Biologics
• Personalis, Inc.
• ImmuneXperts SA
• Celentyx Ltd.
• Gen Script Biotech Corporation
• BPS Biosciences, Inc.
• Horizon Discovery Group plc
• Aquila Biomedical
• Explicyte Immuno-Oncology
• DiscoverX Corporation
• HD Biosciences Co., Ltd
• Crown Bioscience, Inc.
• Promega Corporation

Recent Developments

• In February 2024, TRACER, the Transformative Rare Cancer Initiative, with a $ 2.5 million grant from the U.S. FDA (the United States Food and Drug Administration), was launched by the Fred Hutch Cancer Center’s Dr. Taran Gujral.
• In March 2024, Dr. Reddy's Laboratories launched the first biosimilar product for cancer treatment, the drug Versavo (bevacizumab), in the UK market. Versavo is used to treat many cancers, including metastatic breast cancer, ovarian cancer, advanced cervical cancer, metastatic renal cell carcinoma, recurrent glioblastoma, advanced non-squamous non-small lung cancer, and metastatic colorectal cancer.
• In March 2024, Clasp launched a $150 million & plan for precision cancer immunotherapies. The company was developing a type of T-cell engager that matches patients with tumor signatures and specific immune systems.
• In April 2024, a launch with more than $1 billion in capital-committed funding was announced by an AI-enabled drug discovery and development company, Xaira Therapeutics.

Segments Covered in the Report

By Service

• Target Identification and Validation
• Lead Screening and Characterization
• Cell-based Assays

By Cancer

• Lung
• Breast
• Colorectal
• Melanoma
• Prostate
• Head & Neck
• Ovarian
• Pancreatic

By Drug

• Monoclonal Antibodies
• Immunomodulators
• Cancer Vaccines and Oncolytic Viral Therapy
• Others

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa